AEMD - Aethlon Medical, Inc.
| Previous Close | 1.1900 |
| Open | 1.1800 |
| Bid | 1.1500 x 900 |
| Ask | 1.2000 x 1400 |
| Day's Range | 1.1600 - 1.2000 |
| 52 Week Range | 0.8200 - 2.0400 |
| Volume | 5,477 |
| Avg. Volume | 75,010 |
| Market Cap | 20.646M |
| Beta (3Y Monthly) | 1.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3420 |
| Earnings Date | Feb 7, 2019 - Feb 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- Zacks Small Cap Research•6 hours ago
AEMD: Pivot Towards Cancer Makes Sense. FDA Filing For Breakthrough Device in Cancer
Aethlon (AEMD) reported financial results for their fiscal second quarter ending September 30th and provided an operational update. As we had expected, no revenue was generated in the quarter – we do, however anticipate that revenue will return in fiscal Q3 and reflect initial progress under the recently awarded NCI grant evaluating Hemopurifier in the removal of breast cancer derived exosomes from the blood.
- GlobeNewswire•8 hours ago
Research Report Identifies Prudential Financial, Second Sight Medical Products, Acushnet, Repligen, Scorpio Tankers, and Aethlon Medical with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•6 days ago
Aethlon Medical Announces Second Quarter Fiscal Year 2019 Results
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, today announced results for its fiscal second quarter ...
- PR Newswire•11 days ago
Aethlon Medical To Release Quarterly Financial Results and Host Conference Call on November 6, 2018
SAN DIEGO , Nov. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health today announced it will issue financial results for ...
- PR Newswire•14 days ago
Aethlon Medical to Present at the NYC Oncology Conference
Aethlon Medical is focused on addressing unmet needs in global health. The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. Additionally, Aethlon owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.
- GlobeNewswire•25 days ago
Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•27 days ago
Aethlon Medical to Present at the 2018 BIO Investor Forum
SAN DIEGO, Oct. 16, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), an immunotherapeutic technology company focused on unmet needs in global health, today announced that its CEO, Jim Joyce, will present at the 2018 BIO Investor Forum on Thursday, October 18, 2018 at 3:15 p.m. Pacific Time. The event is being held at the Westin St. Francis Hotel in San Francisco, California. A live audio webcast of the presentation can be accessed at http://www.aethlonmedical.com/news-media/presentations. A replay of the webcast will be available until January 15, 2019. Aethlon Medical is focused on addressing unmet needs in global health. The Aethlon Hemopurifier® is clinical-stage immunotherapeutic device candidate to combat cancer and life-threatening viral infections. Aethlon Medical is also the majority owner of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression.
- Simply Wall St.•last month
How Financially Strong Is Aethlon Medical Inc (NASDAQ:AEMD)?
While small-cap stocks, such as Aethlon Medical Inc (NASDAQ:AEMD) with its market cap of US$20m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...
- PR Newswire•2 months ago
Aethlon Medical Receives National Cancer Institute Award
The Aethlon Hemopurifier is a first-in-class therapeutic technology designed for the rapid depletion of circulating viruses and cancer promoting exosomes. The FDA has designated the Hemopurifier as a "Breakthrough Device" for the treatment of life-threatening viruses for which there are no approved therapies.
- Zacks Small Cap Research•2 months ago
AEMD: Compassionate Use, Real-World Data, Awaiting FDA Final Guidance
Revenue of $150k represented the final payment from the phase I NCI cancer grant. A subsequent, phase 2 contract worth approximately $1.5M over two years, could follow – AEMD’s application for which is expected to be submitted later this year. Updates to several of the development programs were provided on the call, including that related to Hemopurifier under the Breakthrough Device designation, Hemopurifier’s potential role in cancer therapy and updates in the ESI segment – including CTE/TauSome study enrollment status and potential new opportunities.
- GlobeNewswire•3 months ago
Research Report Identifies Ball, Aethlon Medical, NeoGenomics, Del Taco Restaurants, Arconic, and Agilysys with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ball ...
- PR Newswire•3 months ago
Aethlon Medical Announces First Quarter Fiscal Year 2019 Results
SAN DIEGO , Aug. 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...
- ACCESSWIRE•3 months ago
Aethlon Medical, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Aethlon Medical, Inc. (NASDAQ: AEMD ) will be discussing their earnings results in their Q1 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern Time. ...
- PR Newswire•3 months ago
Aethlon Medical To Release Financial Results for the First Quarter Fiscal Year 2019 and Host Conference Call on August 8, 2018
SAN DIEGO , Aug. 2, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense today announced it will issue financial ...
- Simply Wall St.•5 months ago
Loss-Making Aethlon Medical Inc (NASDAQ:AEMD) Expected To Breakeven
Aethlon Medical Inc’s (NASDAQ:AEMD): Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. On 31 March 2018, theRead More...
- PR Newswire•5 months ago
Guy Cipriani Joins Aethlon Medical's Board of Directors
SAN DIEGO, June 25, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Guy Cipriani to its Board of Directors. Mr. Cipriani qualifies as an independent director under the Nasdaq Rules. Mr. Cipriani is a business executive with nearly 20 years of experience in the pharmaceutical and biotech industries.
- Zacks Small Cap Research•5 months ago
AEMD: AEMD In Active Discussions With FDA Regarding Hemopurifier Pathway
Revenue of $75k, which was largely inline with our $89k estimate, relates entirely to a second milestone from the NCI cancer grant. Subsequent to the close of fiscal 2018, AEMD billed an additional $112k for work completed under this grant.
- PR Newswire•5 months ago
Aethlon Medical Announces Fiscal 2018 Results
SAN DIEGO , June 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...
- PR Newswire•5 months ago
Aethlon Medical To Release 2018 Fiscal Year End Financial Results and Host Conference Call on June 8, 2018
Also Presenting at 2018 BIO International Convention on June 6, 2018 SAN DIEGO , May 31, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs ...
- Simply Wall St.•6 months ago
Are Aethlon Medical Inc’s (NASDAQ:AEMD) Interest Costs Too High?
Aethlon Medical Inc (NASDAQ:AEMD) is a small-cap stock with a market capitalization of US$21.04M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...
- ACCESSWIRE•7 months ago
GVC Capital and Trickle Research Announce Presenter Schedule for Rocky Mountain MicroCap Conference II in Denver on April 24, 2018
DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II ...
- PR Newswire•8 months ago
Study of Blood Test to Detect and Monitor Chronic Traumatic Encephalopathy (CTE) in Former NFL Players Set for Kick-Off in Phoenix
PHOENIX and SAN DIEGO, March 22, 2018 /PRNewswire/ -- Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (AEMD), today announced the initiation of an Institutional Review Board (IRB) approved protocol for a research study involving retired NFL players and a data-supported biomarker candidate to potentially detect and monitor Chronic Traumatic Encephalopathy (CTE) in living individuals. The sample collection will be conducted in collaboration with Kendall Van Keuren-Jensen, Ph.D., co-director of the Translational Genomics Research Institute's (TGen) Center for Noninvasive Diagnostics, for biomarker discovery projects. With the approval of the protocol, investigators plan to initiate screening of candidate participants in the coming weeks. The study will enroll former NFL players, who are at high-risk of suffering from CTE, and control subjects who didn't participate in activities that involved repetitive head trauma.
